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Evidence on relative treatment effects concerning OS, progression-free survival 
(PFS) and discontinuation due to any reason (treatment persistence) and adverse 
events (tolerability) was estimated using a mixed treatment comparison following a 
systematic review of randomized clinical trials enrolling post-menopausal women 
with hormone-sensitive ABC. Health service costs were included and a lifetime 
perspective adopted (5% annual discount rate). Results: Everolimus+exemestane 
is estimated to significantly delay progression or death (HR PFS = 0.53; 95% CI: [0.37; 
0.76]) and to increment life expectancy by 6.8 months in comparison to fulvestrant 
(HR OS = 0.82; 95% CI: [0.50; 1.36]), resulting in a 0.45 discounted life year (LY) gain. 
Corresponding incremental health service costs amount to 16,544€ /patient starting 
everolimus+exemestane. This results in an incremental cost-effectiveness ratio 
of 36,703€ /LY gained with everolimus+exemestane. Probabilistic sensitivity analy-
sis showed a greater than 60% probability of everolimus+exemestane being cost-
effective against fulvestrant, at a willingness to pay of 50,000€ /LY. ConClusions: 
We evidence how valuable information from clinical trials can be pooled and used 
to inform about the therapeutic and economic value of guideline recommended 
therapies for advanced breast cancer.
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objeCtives: To assess the cost-effectiveness of pembrolizumab to treat unre-
sectable or metastatic melanoma in patients progressing after treatment with 
ipilimumab, and if BRAFv600positive mutation, a BRAF inhibitor. The relevant com-
parator is English best supportive care (BSC), including dacarbazine. Methods: 
A three-state partitioned survival model was developed to estimate the cost-
effectiveness of pembrolizumab compared with BSC over a 30 year time horizon. 
Efficacy and quality of life were derived from KEYNOTE-002, a phase II clinical 
trial comparing pembrolizumab to investigators choice of chemotherapy. Since 
overall survival (OS) data were affected by a high degree of crossover, various 
statistical models were used to adjust for crossover with the 2-stage adjust-
ment, using progression as a secondary baseline, found to be the most appro-
priate. Pembrolizumab OS was extrapolated using long-term ipilimumab data, 
supported by results of the KEYNOTE-002 clinical trial, and melanoma clinical 
experts’ feedback on commonality of expected long-term survival profile. Quality 
of life was based on time to death health states using KEYNOTE-002 EQ-5D data. 
Adverse events were incorporated based upon KEYNOTE-002 data which showed 
a favourable safety profile when compared to chemotherapy, with grade 3-5 
adverse events numerically higher in the chemotherapy control arm. Results: 
Pembrolizumab was predicted to increase the life expectancy of patients by 
1.59 years, which corresponds to a gain of 1.19 QALYS. In the base case analy-
sis, the ICER is £42,923 (confidential discount included). These results are sensi-
tive to curve fit parameters for progression-free survival and the hazard-ratio 
for overall survival estimated from the cross-over adjustment and a robust to 
changes in value parameters and assumptions in the cost-effectiveness analy-
sis. ConClusions: As an end of life therapy for English patients with advanced 
melanoma previously treated with ipilimumab, pembrolizumab is a cost-effective 
therapeutic option when compared to best supportive care (including conventional 
chemotherapy).
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rEvisitiNg thE simulatioN EvidENCE for thE iNCrEmENtal Cost-
EffECtivENEss of brEast CaNCEr sCrEENiNg of avEragE-risk womEN
O’Mahony JF
Trinity College Dublin, Dublin, Ireland
objeCtives: Breast cancer screening is established practice in most developed 
countries, typically with a two-year screening interval. The cost-effectiveness evi-
dence supporting screening is primarily from simulation models. It is recognised 
that cost-effectiveness analyses (CEAs) of biennial screening should include trien-
nial strategies as comparators if the incremental cost-effectiveness ratio (ICER) is to 
be correctly estimated. The objective of this study is to assess how many published 
CEAs of breast screening include triennial comparator strategies against which to 
compare biennial screening. Methods: We assessed 26 simulation-based CEAs 
of breast screening of average-risk women identified in a recently published sys-
tematic review. We reviewed how many included triennial comparators to biennial 
screening and assessed the relevant ICERs. Results: Of the 26 CEAs, 18 did not 
include comparators with intervals of three years or more. Therefore the ICER esti-
mates for biennial screening from these studies are on the basis of insufficient com-
parators. Of the remaining studies, six included the necessary triennial comparators. 
Of these, two provide ICERs of biennial screening that are clearly acceptable relative 
to commonly cited willingness to pay thresholds. The results from the remaining 
four studies leave it unclear if biennial screening is cost-effective. ConClusions: 
Despite the widely expressed view that breast screening is cost-effective, the pro-
portion of published CEAs that provide appropriately estimated ICERs of biennial 
screening is small and the number clearly indicating biennial screening is cost-
effective is even smaller. This does not suggest that biennal breast screening is cost-
ineffective, but rather that most CEAs published to date do not present sufficient 
evidence to demonstrate cost-effectiveness.
PCN136
ECoNomiC assEssmENt of EribuliN agaiNst trEatmENt of PhysiCiaN’s 
ChoiCE (tPC) iN taiwaN
Chang CJ1, Chao T2, Park J3, Jones T4, Majethia U5, Ni C6
1Chang Gung University, Tao-Yun, Taiwan, 2Taipei Veterans General Hospital, Taipei, Taiwan, 
3Eisai Korea Inc., Seoul, South Korea, 4Eisai Pharmaceuticals, Hatfield, UK, 5Eisai Inc., Woodcliff 
Lake, NJ, USA, 6Eisai Taiwan Inc., Taipei, Taiwan
PCN131
Cost EffECtivENEss of bortEzomib, rituximab, CyCloPhosPhamidE, 
doxorubiCiN aNd PrEdNisoNE for thE first-liNE trEatmENt of maNtlE 
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objeCtives: Mantle cell lymphoma (MCL) is a rare but aggressive form of non-Hodg-
kin’s lymphoma with one of the poorest outlooks. In Scotland, patients unsuitable 
for stem cell transplantation (SCT) primarily receive rituximab, cyclophosphamide, 
doxorubicin, vincristine and prednisone (R-CHOP). The LYM-3002 trial demonstrated 
that the use of bortezomib, rituximab, cyclophosphamide, doxorubicin and pred-
nisone (VR-CAP) almost doubled progression-free survival (PFS) relative to R-CHOP 
(24.7 vs 14.4 months; HR= 0.63, p< 0.001). The objective of this analysis was to assess 
the cost effectiveness of VR-CAP versus R-CHOP as first-line treatment for MCL-
patients unsuitable for SCT, from the perspective of the Scottish National Health 
Service (NHS). Methods: A cost-effectiveness model was constructed based upon 
line of treatment, progression status and survival; extrapolating LYM-3002 clinical 
trial data using parametric models fit to PFS, overall survival (OS) and treatment-
free interval Kaplan–Meier curves. Utilities were derived from trial-based EQ-5D 
data, supplemented with published values for long-term health status. Resource 
use including second-line treatment was taken from the LYM-3002 trial and UK 
clinician advice. Costs were derived from standard UK sources. Probabilistic and 
structural sensitivity analyses were conducted to assess the uncertainty of the 
results. Results: Total lifetime costs were £45,453 and £26,291 for VR-CAP vs. 
R-CHOP. Treatment with VR-CAP resulted in greater life years (7.49) compared to 
R-CHOP (6.58), and quality-adjusted life years (QALYs), 4.05 and 3.31 for VR-CAP and 
R-CHOP, respectively. Thus the additional cost associated with VR-CAP was partially 
offset by additional benefit; resulting in an incremental cost-effectiveness ratio of 
£23,020. Probabilistic sensitivity analysis estimated an 82% chance that VR-CAP 
was cost effective below £30,000/QALY. The model was most sensitive to extrapola-
tion assumptions for PFS and OS and utility associated with post-progression from 
second-line treatment. ConClusions: VR-CAP is a cost-effective treatment for 
previously untreated patients with MCL who are unsuitable for SCT in NHS Scotland.
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objeCtives: Genetically-targeted therapies are both promising and costly advances 
in the field of oncology. This study aims to evaluate the cost-effectiveness of vemu-
rafenib versus ipilimumab as first-line treatments in patients with BRAF V600 
mutation-positive unresectable or metastatic melanoma from a Spanish health-
care system perspective. Methods: We performed a cost-effectiveness analysis to 
compare both strategies for patients with BRAF positive metastatic melanoma using 
a probabilistic model. Since head-to-head trials are not available, overall (complete 
and partial) response rates were obtained from the phase III randomized-controlled 
trials of vemurafenib (57.0%; 95% CI 51.6-65.2%) and ipilimumab (15.2%; 95% CI 12.2-
18.2%). The cost of treatment regimens was calculated using the recommended dose 
schedules as per the Summary of Product Characteristics. The treatment duration 
with vemurafenib was 6.9 months (median progression-free survival). Four doses 
of ipilimumab were considered. The prices used in the analysis correspond to those 
currently approved in Spain (in EUR, 2015).Monte-Carlo simulation was chosen as 
it allows simulating the effect of changes in different parameters obtained from 
clinical studies and other sources to describe real-life distributions. Parameters 
used in the simulation were the progression free survival, body weight and overall 
response rates. Additional threshold sensitivity analyses for possible ipilimumab 
price discounts were performed. Results: 1,000 model iterations were generated. 
The cost per overall response with vemurafenib and ipilimumab was € 111,928 
(95% CI € 108,403; € 115,969) and € 447,462 (95% CI € 370,285; € 538,214) respectively. 
Therefore, the cost of ipilimumab per patient that responds to treatment would be 
4.0 (3.4-4.6) times greater than treating with vemurafenib. The cost per responder 
would be equal amongst both treatments, only with a discount of 71.1% in the price 
of ipilimumab. ConClusions: In BRAF V600 mutation-positive unresectable or 
metastatic melanoma, first-line vemurafenib could reduce the health care costs 
per overall response in comparison to ipilimumab.
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thEraPEutiC aNd ECoNomiC valuE of EvErolimus Plus ExEmEstaNE for 
thE trEatmENt of PostmENoPausal womEN with hormoNE rECEPtor-
PositivE, hEr2/NEu NEgativE advaNCEd brEast CaNCEr
Félix J, Almeida J, Ferreira D, Rabiais S, Vandewalle B
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objeCtives: Up to 70% of women with hormone-sensitive advanced breast cancer 
(ABC) need further therapy lines following first-line hormonal therapy. Although 
treatment guidelines provide useful recommendations for treating patients with 
ABC they rarely compare different treatment options or provide guidance on how to 
optimize their value. This research aimed to assess the therapeutic and economic 
value of everolimus 10mg plus exemestane 25mg daily (everolimus+exemestane) in 
comparison to fulvestrant (500mg intramuscularly on days 0, 14 and 28, and every 28 
days thereafter) for the treatment of hormone receptor-positive, HER2/neu negative 
ABC postmenopausal women who failed first-line hormonal therapy. Methods: 
We used a discrete-time, state-transition model to estimate the long term overall 
survival (OS) and treatment costs in ABC patients failing first-line hormonal therapy. 
A454  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
PCN139
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hEr2-PositivE brEast CaNCEr iN italy
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objeCtives: The aim of this study was to evaluate the cost-effectiveness of 
pertuzumab in combination with trastuzumab and docetaxel as neo-adjuvant 
treatment for locally advanced, inflammatory, or early stage breast cancers that 
overexpress Human Epidermal growth factor Receptor 2 (HER2), from the Italian 
National Health System (SSN) perspective. Methods: A six state Markov model 
was used to estimate outcomes and costs over a 50-year time horizon. Patients 
were assumed to receive standard neo-adjuvant therapy containing trastuzumab 
and docetaxel or the same regimen plus pertuzumab. Transition probabilities to 
progressive disease and death were based on total pathological complete response 
(pCR) rates observed in the NeoSphere study. A second analysis was carried out 
in which progression-free survival (PFS) was directly modelled on observed 
data. Expected survival was adjusted by utility weights for health states derived 
from literature. Direct medical unit costs were collected from official and pub-
lished Italian sources. Costs and health gains were discounted at an annual 3% 
rate. Probabilistic sensitivity analysis (PSA) was carried out to evaluate uncer-
tainty. Results: Pertuzumab combination was associated with increased QALYs 
and costs relative to standard neo-adjuvant regimen. Acquisition drug cost of 
pertuzumab was the primary contributor to the difference in costs, partially off-
set through the prevention of relapse and worsening. The estimated ICERs range 
between € 3,000 and € 19,000 per QALY. In PSA, pertuzumab combination has very 
high probability of being cost effective relative to standard regimen for a WTP 
threshold of € 40,000 per QALY gained. ConClusions: Breast cancer with HER2 
overexpression is associated with increased tumour aggressiveness, higher rates 
of recurrence and mortality. In the neo-adjuvant setting, pertuzumab in combina-
tion with trastuzumab and docetaxel is expected to be more effective (increased 
probability to reach higher pCR rate and longer PFS) than standard regimen, at a 
favourable cost per QALY gained.
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a Cost utility aNalysis of CEtuximab for 1st-liNE trEatmENt of 
ras wild-tyPE mEtastatiC ColorECtal CaNCEr: a summary of thE 
submissioN to all walEs mEdiCiNEs stratEgy grouP (awmsg)
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objeCtives: Colorectal cancer is the third most common cancer in Wales, with 2444 
new cases reported in 2012. Incidence increased by 28.5% between 2002 and 2012. 
While survival rates in colorectal cancer are improving globally, the UK continues to 
lag behind other major economies. Recent evidence demonstrates that cetuximab 
can result in significant life extension when added to chemotherapy as a first line 
treatment of RAS wild type metastatic colorectal cancer. At present, cetuximab is 
funded in Wales mainly through Individual Patient Treatment Requests which are 
increasing in number due to the rising demand from both patients and physicians. 
An evidence submission was submitted to AWMSG to highlight this clinical benefit 
and assess the cost effectiveness of cetuximab. Methods: An economic model 
was developed to assess the cost effectiveness of cetuximab in the management 
of unresectable RAS wt metastatic colorectal cancer in comparison to comparators 
available in the Welsh NHS; FOLFOX, FOLFIRI, or CAPOX alone. This includes a small 
population of patients with metastases confined to the liver who may subsequently 
be eligible for curative resection after treatment with cetuximab plus chemotherapy. 
The time horizon is 10 years and the discount rate applied to both outcomes and 
costs is 3.5%. Cetuximab Welsh Patient Access Scheme (WPAS) price was used in 
all analyses and the dose was set to fortnightly dosing as typically prescribed in 
Wales. Results: Economic analyses estimated an incremental cost effectiveness 
ratio of £29,512 per QALY gained for cetuximab + FOLFOX compared to FOLFOX 
alone and £35,731 per QALY gained for cetuximab + FOLFIRI compared to FOLFIRI 
alone. ConClusions: These analyses demonstrate that cetuximab is a cost effec-
tive treatment and a good use of NHS Wales resources through stratification of 
RAS wild type patients who are likely to respond to treatment and offer patients a 
life-extending treatment option.
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bACkgRound: In September 2014 the European Commission granted market-
ing authorisation for idelalisib with rituximab (I+R) for the treatment of chronic 
lymphocytic leukaemia (CLL) in previously treated patients and treatment-naïve 
patients with a 17p deletion or TP53mutation. objeCtives: This study evaluated 
the cost effectiveness of I+R in previously-treated patients according to their eli-
gibility for chemo-immunotherapy in England and Wales. Methods: A 5-state 
Markov model was constructed from a National Health Service (NHS) perspective 
over a lifetime horizon. Study 116 contained 220 patients for whom chemo-immu-
notherapy was unsuitable owing to poor previous response to such treatment, 
the presence of 17p deletion or TP53mutation, or their fitness, randomised 1:1 
to I+R (intervention) or rituximab with placebo (comparator). Intervention-arm 
data from Study 116 were used to inform the effectiveness of I+R in terms of 
response, time on treatment, progression-free and overall survival. Comparator-
arm data from Study 116 were used to inform the effectiveness of (i) rituximab 
monotherapy, and using further assumptions, (ii) ofatumumab monotherapy and 
objeCtives: The objective of this study was to estimate Incremental Cost-
Effectiveness Ratio(ICER) of utilizing eribulin against Treatment of Physician’s 
Choice (TPC) for third line treatment of Metastatic Breast Cancer(MBC) in 
Taiwan. Methods: Efficacy and safety data was obtained from a multicentre phase 
III clinical trial (EMBRACE) comparing eribulin against TPC. A five-year partitioned 
survival cost-effectiveness analysis(CEA) with a Quality-adjusted Time Without 
Symptoms and Toxicity(Q-TWiST) as the effectiveness measure was developed. 
Costs included in the model were drugs & administration, post-treatment resource 
use, toxicity management and indirect treatment costs. Cost effectiveness was eval-
uated using the Gamma distribution for Overall Survival(OS), Weibull for Progression 
Free Survival(PFS), response duration and, toxicity time. Health state utilities were 
applied to each component and aggregated. In base-case analysis, 3% discount-
ing was applied for both benefits and costs. Deterministic sensitivity analysis was 
used to evaluate sensitivity of the key variables. Results: OS based on Gamma 
extrapolation was 17.26 months in eribulin group versus 14.39 months in TPC group 
for a difference of 2.87 months. Mean time without progressive disease was 4.68 
months for eribulin and 3.96 months for TPC for a difference of 0.72 months. The 
Quality Adjusted Life Years were 0.83 in the eribulin group compared to 0.70 in TPC 
group for a mean incremental improvement of 0.13 years. Treatment costs were 
NTD 351,875 for eribulin and NTD 113,552 for TPC for a difference of NTD 238,323. 
In base-case analysis, the ICER with discounting was NTD 1,823,482. Survival time 
was most sensitive variables on the ICER in this CEA. ConClusions: With an ICER 
of NTD 1,823,482 compared to TPC, eribulin was found to be cost-effective in third 
and later line MBC population in Taiwan. Given the limited number of effective 
therapeutic options available to these patients, eribulin represents a valid option 
for optimizing treatment pathways.
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objeCtives: To estimate the incremental cost per life-year gained (LYG) of aflibercept 
in combination with FOLFIRI as second-line treatment in metastatic colorectal cancer 
(mCRC) in Best Efficacy Subgroup (BES) patients previously treated with oxaliplatino 
compared to FOLFIRI. Methods: A post-hoc analysis of the VELOUR clinical trial 
revealed an improvement of aflibercept efficacy in a specific subgroup. BES was com-
posed by patients with performance status (PS) 0 with any number of metastatic sites 
or PS 1 with < 2 metastatic sites, exclusive of adjuvant fast relapsers. A Markov model 
with 3 health states (stable disease, progression and death) was used to estimate 
lifetime costs and outcomes (2-weeks cycle duration). Transition from stable disease 
to progression implied the interruption of second-line treatment and administra-
tion of a third-line chemotherapy (72%) or best supportive care (28%). According to 
the National Health System (NHS) perspective only direct costs were considered. 
Cost estimation (€ , 2015) included pharmaceutical and administration cost, adverse 
event management and hospital and medical visits consumption. Ex-factory price 
with mandatory deduction was applied for drug cost estimation. Costs and outcomes 
were 3% annually discounted. Sensitivity analyses (SA) were performed. Results: 
Administration of aflibercept + FOLFIRI as second-line treatment on BES was more 
effective than FOLFIRI, yielding 1.92 LYG (23 life-months gained) compared to 1.55 
LYG (18.6 months). Aflibercept + FOLFIRI accounted a total cost of € 40,449, compared 
to € 25,698 estimated for FOLFIRI. The incremental cost-effectiveness analysis pro-
vided a € 33,373/LYG ratio for aflibercept in combination with FOLFIRI versus FOLFIRI 
for BES. SA results confirmed the model robustness. ConClusions: According to 
a post-hoc analysis, aflibercept in combination with FOLFIRI could increase overall 
survival versus FOLFIRI on BES. Aflibercept + FOLFIRI could be an efficient strategy for 
second-line treatment in specific mCRC patients for the Spanish NHS.
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Cost-EffECtivENEss of CardioProtECtivE EffECt of dExrazoxaNE 
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Paladio-Hernández JÁ1, Martínez-Morales J2
1Independent Consultant, Cuautitlán Izcalli, Mexico, 2UACH, Hidalgo del Parral, Mexico
objeCtives: The problem of anthracycline-induced clinical heart failure is an 
important public health concern as it may not be seen for many years and remains 
a life-long threat. We performed a cost-effectiveness analysis of the cardioprotec-
tive effect of Dexrazoxane in advanced/metastatic breast cancer patients treated 
with anthracycline-based chemotherapy in México. Methods: A decision tree 
model was developed in order to compare dexrazoxane with no treating. The time 
horizon was one year. The main data for dexrazoxane efficacy (surgery require-
ment and functional loss) was obtained from two open label non-comparative 
studies. Main costs taken into account were the drug costs, administration and 
monitoring and surgical costs. Results: Dexrazoxane may lead to important 
savings for the Mexican public health system when it is compared to no treat-
ing. The results derived from the model indicate that Dexrazoxane is associated 
with less cardiac events (39% versus 13%, P < 0.001) and a lower and less severe 
incidence of congestive heart failure (11% versus 1%, P < 0.05) which represent a 
saving of 200,000 USD per patient treated. Tumor response rate was unaffected 
by dexrazoxane therapy. The frequency of adverse events was similar between 
groups and there were no significant between-group differences in the number 
of dose modifications/interruptions. ConClusions: Dexrazoxane is a dominant 
alternative vs no treating since it significantly reduced the occurrence and severity 
of anthracycline-induced cardiotoxicity in patients at increased risk of cardiac 
dysfunction due to previous anthracycline treatment without compromising 
the antitumor efficacy of the chemotherapeutic regimen at a lower cost than no 
treating
